Literature DB >> 16857456

Percutaneous renal cryoablation.

Sompol Permpongkosol1, Matthew E Nielsen, Stephen B Solomon.   

Abstract

Percutaneous renal cryoablation (PRC) has been gaining acceptance as a minimally invasive option for the treatment of patients with solid renal masses. Herein, we reviewed the historical development of PRC, relevant contemporary clinical data, and future directions of percutaneous approaches to renal masses. Early experience suggests that PRC has the potential to offer an alternative treatment for patients with small renal masses, with the advantages of decreased treatment-associated morbidity and spared renal function. Ultrasound, computed tomography, magnetic resonance imaging, and positron-emission tomography have all been explored as potential solutions to the challenges of image guidance and follow-up; distinct advantages and disadvantages of each are reviewed here. Encouraging early results regarding oncologic efficacy, rate of complications, and overall costs support the continued evaluation of PRC. Longer-term oncologic follow-up is essential if the potential application of this minimally-invasive technique to a broader spectrum of patients with renal masses is to be determined.

Entities:  

Mesh:

Year:  2006        PMID: 16857456     DOI: 10.1016/j.urology.2005.12.052

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  Prospects in percutaneous ablative targeting: comparison of a computer-assisted navigation system and the AcuBot Robotic System.

Authors:  Richard Pollock; Pierre Mozer; Thomas J Guzzo; Jonathan Marx; Brian Matlaga; Doru Petrisor; Bogdan Vigaru; Shadie Badaan; Dan Stoianovici; Mohamad E Allaf
Journal:  J Endourol       Date:  2010-08       Impact factor: 2.942

2.  Saline Mobilization of the Colon during Percutaneous Renal Cryoablation.

Authors:  Anthony J Polcari; Marc A Borge; Kent T Perry
Journal:  Semin Intervent Radiol       Date:  2007-09       Impact factor: 1.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.